Full text is available at the source.
Do Glucagonlike Peptide-1 Receptor Agonist and Sodium-glucose Co-transporter 2 Inhibitor Prescriptions in Germany Reflect Recommendations for Type 2 Diabetes with Cardiovascular Disease of the ADA/EASD Consensus Report?
Do Prescriptions of Two Diabetes Drugs in Germany Follow Guidelines for Type 2 Diabetes with Heart Disease?
AI simplified
Abstract
Overall, 35% of patients with newly diagnosed type 2 diabetes were treated with glucose-lowering drugs during the first year after diagnosis.
- GLP-1 receptor agonists (GLP-1RA) were prescribed to only 2.4% of patients, while sodium-glucose cotransporter 2 inhibitors (SGLT2i) were prescribed to 8.5%.
- Following the 2018 ADA/EASD consensus guidelines, the prescription rates for GLP-1RA and SGLT2i increased among patients with and without pre-existing cardiovascular disease.
- The use of GLP-1RA rose from 5.7% to 9.2% in patients with cardiovascular disease and from 5.2% to 7.6% in those without.
- SGLT2i use increased from 13.9% to 20.4% in patients with cardiovascular disease and from 12.1% to 16.6% in those without.
- Obesity was associated with the highest likelihood (odds ratio of 4.5) of receiving GLP-1RA, while cardiovascular disease had a moderate association with prescriptions for both SGLT2i and GLP-1RA.
AI simplified